The newly approved treatment, SKINVIVE by JUVÉDERM, is now the first and only hyaluronic acid injectable cleared specifically for improving neck appearance
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
With standout ADC and t-cell engager response data across hard-to-treat cancers
After Phase 3 results show major hair regrowth gains
The submission is backed by positive results from the Phase 3 AFFIRM study
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Highlights Mirvetuximab-based regimen promise
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
